VCYT Q4 2019 Earnings — Veracyte, Inc. Revenue & Financial Results | Market Cap Arena

VCYTVeracyte, Inc.

$3B

Q4 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$30M+15.5% YoY

Gross Profit

$20M66.0% margin

Operating Income

-$8M-27.6% margin

Net Income

-$7M-25.1% margin

EPS (Diluted)

$-0.15

QoQ Revenue Growth

-4.0%

Cash Flow

Operating Cash Flow

$2M

Free Cash Flow

$690,000

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$275M

Total Liabilities

$36M

Stockholders' Equity

$239M

Cash & Equivalents

$159M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$30M	$26M	+15.5%
Gross Profit	$20M	$17M	+15.0%
Operating Income	-$8M	-$3M	-168.1%
Net Income	-$7M	-$3M	-140.2%